Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18422032 | 0.97 | GAA (0.53) | GAAMAPTKMT2AALDH1A1CA12 | |
| SCHEMBL31322749 | 0.84 | GAA (0.47) | GAAMAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL10991781 | 0.78 | CYP3A4 (0.41) | GAAMAPTKMT2AHTTTDP1 | |
| Bromide SCHEMBL20984539 | 0.76 | CYP3A4 (0.39) | GAAMAPTKMT2AHTTTDP1 | |
| Hydrochloric Acid SCHEMBL20984266 | 0.76 | CYP3A4 (0.39) | GAAMAPTKMT2AHTTTDP1 | |
| SCHEMBL18421429 | 0.74 | TSHR (0.35) | GAA | |
| SCHEMBL1117704 | 0.74 | GAA (0.45) | GAAMAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL10616863 | 0.73 | NOTUM (0.34) | GAAMAPTKMT2AALDH1A1CA12 | |
| SCHEMBL29866474 | 0.73 | GAA (0.41) | GAAMAPTKMT2ACA1CA2 | |
| SCHEMBL25573050 | 0.73 | GAA (0.41) | GAAMAPTKMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3357925-B1 | SALT TYPE AND CRYSTAL TYPE OF 4H-PYRAZOLO [1, 5-ALPHA]BENZIMIDAZOLE COMPOUND AND PREPARATION METHOD AND INTERMEDIATE THEREOF | HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) | 2021-10-27 | — | — | EP | disclosed |
| US-10428073-B2 | Salt type and crystal type of 4H-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2019-10-01 | — | — | US | disclosed |
| EP-3130592-B1 | ANALOGUES OF 4H-PYRAZOLO[1,5- ]BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) | 2019-08-14 | — | — | EP | disclosed |
| EP-3130592-B1 | ANALOGUES OF 4H-PYRAZOLO[1,5- ]BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) | 2019-08-14 | — | — | EP | disclosed |
| CN-106459057-B | Analogs of 4H-pyrazolo [1,5- α ] benzimidazole compounds as PARP inhibitors | 湖北生物医药产业技术研究院有限公司 | 2019-06-07 | — | — | CN | disclosed |
| EP-3357925-A1 | SALT TYPE AND CRYSTAL TYPE OF 4H-PYRAZOLO [1, 5-ALPHA]BENZIMIDAZOLE COMPOUND AND PREPARATION METHOD AND INTERMEDIATE THEREOF | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (CN) | 2018-08-08 | — | — | EP | disclosed |
| US-9856262-B2 | Analogues of 4H-pyrazolo[1,5-a] benzimidazole compound as PARP inhibitors | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2018-01-02 | — | — | US | disclosed |
| US-9856262-B2 | Analogues of 4H-pyrazolo[1,5-a] benzimidazole compound as PARP inhibitors | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2018-01-02 | — | — | US | disclosed |
| EP-3130592-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5- ]BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (CN) | 2017-02-15 | — | — | EP | disclosed |
| EP-3130592-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5- ]BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (CN) | 2017-02-15 | — | — | EP | disclosed |
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2017-02-02 | — | — | US | disclosed |
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2017-02-02 | — | — | US | disclosed |
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2017-02-02 | — | — | US | disclosed |
| WO-2015154630-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-Α]BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | 南京明德新药研发股份有限公司 | 2015-10-15 | — | — | WO | disclosed |
| CN-104974161-A | 4H-pyrazolo[1,5-[alpha]]benzimidazole compound analogue as PARP inhibitor | NANJING MINGDE NEW DRUG RES AND DEV CO LTD | 2015-10-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | PARP1, PARP2, PARP11 | GAA 2421/4885MAPT 2532/4885KMT2A 469/4885 |
| US-10428073-B2 | Salt type and crystal type of 4H-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof | REN, BRI3BP, KCNJ11 | GAA 2904/4885MAPT 2501/4885KMT2A 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.